OpenNashPodcasts

Person

Chris Gibson

Chris Gibson is the co-founder of Recursion, a biotech company, and this page collects what he said on the Business Of Biotech podcast about using AI and computational biology to find new medicines. He covered how Recursion began in November 2013 with an NIH grant application, and how it was funded by one institutional investor, angels, its founders and grants until September 2016.

Gibson also described Recursion's robotic laboratory, which he said runs about 2 million experiments a week and has produced over a billion cell images. He discussed its five clinical programs, partnerships with Roche, Genentech and Bayer, and its work on cerebral cavernous malformation, a disease he knows of no other company pursuing.

1 episodes · 22 quoted claims

Chris Gibson joined Dean Lee's laboratory at the University of Utah in 2009 as an MD-PhD student.

“I came to the University of Utah in 2009 for an MD-PhD, and I was lucky enough to join the laboratory of a guy named Dean Lee.”

Business Of Biotech · 0:03:46

Dean Lee, a Recursion co-founder, is president of Merck Research Labs and remains on Recursion's board.

“Dean is now the president of Merck Research Labs. He's one of my co-founders. He's on the board of Recursion still today”

Business Of Biotech · 0:03:46

In a cerebral cavernous malformation animal model, simvastatin trended toward making the animals worse rather than rescuing them.

“we used a well-known, widely available FDA-approved drug in that animal model to test our hypothesis. And while there's lots of reasons why this could have happened, what we found was that that particular drug, this was simvastatin, actually trended towards making the animals worse.”

Business Of Biotech · 0:05:53

Gibson drew on Anne Carpenter of the Broad Institute, who pioneered phenomics, an image-based form of omics.

“I really honed in on work by a woman named Ann Carpenter, who's at the Broad Institute still to this day, who really pioneered a field called phenomics, which is image-based omics”

Business Of Biotech · 0:07:00

A phase two trial of one of Recursion's molecules for cerebral cavernous malformation had been enrolling patients for nine months at the time of the interview.

“the phase two trial of one of those molecules for patients with cerebral cavernous malformation has now been enrolling patients for nine months.”

Business Of Biotech · 0:08:06

Recursion started in November 2013 and its first step was writing a direct-to-phase-two SBIR grant application to the NIH.

“So we started out in November of 2013. Very first thing we did was start writing a direct to phase two SBIR grant to the NIH.”

Business Of Biotech · 0:11:13

Recursion received an almost perfect score on its NIH grant in July 2014, but funding took another eight or nine months to arrive.

“We got an almost perfect score on that grant in July of 2014. Still took another eight or nine months to get the money”

Business Of Biotech · 0:11:13

Until September 2016, Recursion was funded by one institutional investor, friends-and-family angels, its founders and NIH grants.

“for the first almost three years until September of 2016, we were funded by one institutional investor, some friends and family angels and ourselves and the NIH.”

Business Of Biotech · 0:11:39

Recursion's robotic laboratory runs about 2 million experiments a week, up to 2.2 million.

“we have a giant laboratory full of robots where we do about 2 million experiments a week, up to 2.2 million experiments a week.”

Business Of Biotech · 0:14:18

Recursion has generated over a billion cell microscopy images that form its core dataset.

“We've generated over a billion of these images. and those are our core data set.”

Business Of Biotech · 0:16:38

Recursion has knocked out every human gene in multiple cell types and profiled nearly a million molecules at multiple doses in one cell type.

“We've now knocked out every gene in the human genome in multiple human cell types. We've profiled nearly a million molecules at multiple doses in one cell type”

Business Of Biotech · 0:19:05

Gibson says every feature film ever made in 1080p would total about four petabytes, while Recursion holds about 20 petabytes.

“if you took every movie in human history, in every language, like every feature length film in every language in 1080p high definition, you're talking about four petabytes. And we have about 20.”

Business Of Biotech · 0:20:31

Recursion's April 2020 preprint predicted remdesivir would help against COVID-19 and found hydroxychloroquine did nothing in its assay.

“we predicted that remdesivir was going to be positive. It was going to help in that context. We demonstrated that hydroxychloroquine did absolutely nothing in that context.”

Business Of Biotech · 0:22:40

Gibson says Recursion's COVID-19 predictions were right for eight of nine drugs so far, with dexamethasone being the miss.

“The one we got wrong so far is dexamethasone for a variety of a variety of reasons.”

Business Of Biotech · 0:23:08

About 800 machine learning teams competed on Kaggle using a Recursion-released dataset.

“There's been a big competition run with 800 machine learning teams on one of the core datasets we released at Google, a company called Kaggle”

Business Of Biotech · 0:23:08

Recursion has five clinical programs, four of which are molecules not designed by its chemists but repurposed into new disease contexts.

“we now have five programs in the clinic. Four of those programs are molecules that our chemists did not design.”

Business Of Biotech · 0:28:02

Project Gamma is a Recursion program targeting HRD-negative ovarian cancer.

“We call it Project Gamma. And it is focused in HRD-negative ovarian cancer.”

Business Of Biotech · 0:31:04

Recursion signed a collaboration with Roche and Genentech lasting more than a decade, covering neuroscience and one oncology indication.

“In December, almost exactly a year ago, December last year, we signed a huge collaboration with Rosh and Genentech to deploy our technology in partnership with them for more than a decade”

Business Of Biotech · 0:36:05

Recursion also has a partnership with Bayer in fibrosis.

“We're also partnered with Bayer and Fibrosis, another area where these are huge areas of unmet need.”

Business Of Biotech · 0:37:14

Gibson says cerebral cavernous malformation has about six times as many symptomatic patients in the US and Europe as cystic fibrosis, yet he knows of no other company pursuing it.

“there's six times as many symptomatic patients in the US and Europe as cystic fibrosis. But yet there's no company that we are aware of going after it.”

Business Of Biotech · 0:37:44

Gibson says the genes that cause cerebral cavernous malformation encode three scaffolding proteins, making the disease mechanism hard to trace.

“The genes that cause the disease when they're mutated encode three scaffolding proteins, which are kind of hard to trace back.”

Business Of Biotech · 0:38:20

Gibson estimates that humanity understands only about 2 to 3 percent of biology.

“I think we probably only understand like two or 3 % of biology as a species today.”

Business Of Biotech · 0:18:40